Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Achillion Pharmaceuticals Inc.
DescriptionPan-genotypic, second-generation HCV NS5A protein inhibitor
Molecular Target HCV NS5A protein
Mechanism of ActionHCV non-structural protein 5A inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationHepatitis C virus (HCV)
Indication DetailsTreat chronic HCV genotype 1 infection; Treat chronic HCV infection; Treat HCV genotype 1 infection; Treat HCV genotype 1b infection; Treat HCV infection
Regulatory Designation

U.S. - Fast Track (Treat chronic HCV infection)


Johnson & Johnson

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today